AtriCure, Inc. ATRC

Updated: 16 Jun 2026

NASDAQ | Biotech | Medical devices for atrial fibrillation

No signal published yet

We already track AtriCure and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow AtriCure free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Medical devices for atrial fibrillation
We're already tracking AtriCure, Inc. — here are the latest events we've registered

Recent News

  • On May 5, 2026, AtriCure reported first quarter 2026 revenue of $141.25 million, a 14.3% increase year-over-year. The company also participated in the Goldman Sachs Global Healthcare Conference on June 10, 2026.

What Firelda Watch includes for AtriCure, Inc.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of AtriCure, Inc. will be delivered in the same format.

Want to follow AtriCure, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow AtriCure free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

AtriCure, Inc. ATRC
AtriCure — follow and we'll monitor it
Follow AtriCure free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.